Title: STABLE AMORPHOUS AMLODIPINE CAMSYLATE, PROCESS FOR PREPARING SAME AND COMPOSITION FOR ORAL ADMINISTRATION THEREOF

Abstract: This invention relates to a stable, amorphous form of amloidipine camysylate having a high solubility which can be efficiently used in treating cardiovascular diseases.
For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.
STABLE AMORPHOUS AMLODIPINE CAMSYLATE, PROCESS
FOR PREPARING SAME AND COMPOSITION FOR ORAL
ADMINISTRATION THEREOF

Field of the Invention

The present invention relates to an amorphous form of amlodipine
camsylate which has a high solubility and good storage stability, a method for
preparing same and a composition for oral administration comprising same.

Background of the Invention

Amodipine, a generic name for the compound
(3-ethyl-5-methyl-2-(2-aminoethoxy-methyl)-4-(2-chlorophenyl)-6-methyl-1,4
-dihydro-3,5-pyridine dicarboxylate), is a long-term calcium-channel blocker
useful for treating cardiovascular disease such as angina pectoris, hypertension
and congestive cardioplegia.

Amodipine in the form of a free base is useful for pharmaceutical use,
but it shows low stability. Therefore, it is preferably administrated in the
form of a salt of a pharmaceutically acceptable acid.

Korean Patent Publication No. 1995-6710 suggests that a
pharmaceutically acceptable salt must meet four physicochemical
requirements: high solubility, good stability, non-hygroscopicity and
processibility for tablet formulation.

Korean Patent Publication No. 1995-7228 discloses that amlodipine
benzenesulfonate (hereinafter, “amlodipine besylate”) shows suitable
properties for pharmaceutical formulation including high solubility and good
stability.

The present inventors have also suggested in WO 02/079158 A1 that a
crystalline amlodipine camsylate is pharmaceutically stable.
Summary of the Invention

It is a primary object of the present invention to provide an improved form of amlodipine camsylate which has higher stability and solubility than conventional amlodipine salts.

In accordance with one aspect of the present invention, there is provided a method for preparing amorphous amlodipine camsylate by dissolving crystalline amlodipine camsylate in an organic solvent and removing the solvent from the resulting solution.

In accordance with another aspect of the present invention, there is provided amorphous amlodipine camsylate prepared by said method.

In accordance with still another aspect of the present invention, there is provided a pharmaceutical composition for treating cardiovascular disease comprising the amorphous amlodipine camsylate as an active ingredient.

Brief Description of the Drawings

The above and other objects and features of the present invention will become apparent from the following description of the invention taken in conjunction with the following accompanying drawings, which respectively show:

FIG. 1: an X-ray diffraction scan of crystalline amlodipine camsylate;
FIG. 2: an X-ray diffraction scan of the inventive amorphous amlodipine camsylate;
FIG. 3: a differential scanning calorimetry (DSC) scan of crystalline amlodipine camsylate; and
FIG. 4: a differential scanning calorimetry (DSC) scan of the inventive amorphous amlodipine camsylate.

Detailed Description of the Invention

The inventive amlodipine camsylate is substantially amorphous and
thermodynamically stable, and has a high water solubility and good storage stability.

The inventive amorphous amlodipine camsylate can be prepared by dissolving a crystalline form of amlodipine camsylate in an organic solvent and removing the solvent from the resulting solution to obtain an amorphous form of amlodipine camsylate.

Examples of the organic solvent which may be suitably used in the present invention includes ketones such as acetone, alcohols such as methanol or ethanol, nitriles such as acetonitrile, ethers such as tetrahydrofuran and dioxane, esters such as methyl or ethyl acetate, chlorinated solvents such as methylene chloride or chloroform and a mixture thereof, preferably a mixture of ethanol and methylene chloride.

In the inventive method, the used solvent can be removed by rapid solvent evaporation, spray drying, roller drying, solvent precipitation or freeze drying, among which spray drying is preferred since the resulting amorphous amlodipine camsylate is thermodynamically stable. More preferably, a closed cycle spray drying system which can recycle the drying medium may be used in terms of safety and economical efficiency of the process.

In spray drying, an inert gas such as argon, nitrogen and carbon dioxide or air may be used as a drying gas. Inflow and outflow temperatures thereof may be dependent on the boiling point of the solvent used. For example, the inflow temperature may range 50 to 140°C, preferably 60 to 125°C and the outflow temperature may range 45 to 100°C, preferably 50 to 80°C. By employing appropriate spray drying conditions, a product having a uniform particle size may be formed.

In spray or roller drying, a solvent having a boiling point (b.p.) lower than the coagulation point of the inventive product is preferably used. When the drying is carried out under an atmospheric pressure, a solvent having b.p. of 80°C or less may be preferably used. If the drying is carried out under a reduced pressure, a solvent having b.p. higher than 80°C may be used.

In solvent precipitation, crystalline amlodipine camsylate may be dissolved in a suitable organic solvent followed by adding a nonpolar solvent in a suitable amount thereto to induce precipitation of the inventive product.
A preferred nonpolar solvent used in the precipitation include ethers such as isopropyl ether or aromatic hydrocarbons such as benzene and toluene. The nonpolar solvent should be at least partially miscible with the suitable organic solvent. A representative example of solvent combination is dichloromethane/methanol/isoproplylether. The precipitated solid is preferably subjected to rapid filtration and drying, to avoid the formation of crystals. Also, a carrier gas such as air may be used to generate bubbles in solution.

Also, the solvent precipitation may be directly applied to the reaction mixture obtained after the formation of crystalline amlodipine camsylate.

Meanwhile, freeze drying may be carried out at a suitable temperature depending on the freezing point of the solvent used, for example, about 12°C when dioxane is used as a solvent.

The crystalline amlodipine camsylate used for the present invention may be produced according to the method disclosed in WO 02/079158 A1.

The present invention also provides an amorphous amlodipine camsylate composite prepared by dissolving crystalline amlodipine camsylate, surfactants, water-insoluble inorganic carriers or other additives in a suitable organic solvent and removing the solvent from the resulting solution.

Further, the present invention further provides a pharmaceutical composition for treating cardiovascular diseases comprising the inventive amorphous amlodipine camsylate as an active ingredient and pharmaceutically acceptable excipients, carriers or diluents.

The pharmaceutical composition of the present invention may be formulated in accordance with any of the conventional procedures. The formulation may be in the form of a tablet, pill, powder, sachet, elixir, suspension, emulsion, solution, syrup, aerosol, soft or hard gelatin capsule, sterile injectable solution or sterile packaged powder.

Examples of suitable carriers, excipients and diluents are starches, sucrose, lactose, dextrose, gelatin, sorbitol, mannitol, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoates, propylhydroxybenzoates, talc, magnesium stearate and mineral oil. The formulations may additionally include fillers, anti-agglutinating agents, disintegrants, glidants, wetting agents, flavoring agents, emulsifiers, preservatives and the like. The compositions of the
invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after their administration to a mammal by employing any of the procedures well known in the art.

The pharmaceutical composition of the present invention can be administered via various routes including oral, transdermal, subcutaneous, intravenous and intramuscular introduction. In case of human, a typical daily dose of the amorphous amlodipine camsylate may range from about 1.0 to 10.0 mg/kg body weight, preferably 5.0 to 8.0 mg/kg body weight, and can be administered in a single dose or in divided doses.

However, it should be understood that the amount of the active ingredient actually administered ought to be determined in light of various relevant factors including the condition to be treated, the chosen route of administration, the age, sex and body weight of the individual patient, and the severity of the patient's symptom; and, therefore, the above dose should not be intended to limit the scope of the invention in any way.

The present invention also provides a method for preventing or treating cardiovascular diseases in mammals which comprises administering thereto an effective amount of the amorphous amlodipine camsylate.

The present invention will be described in further detail with reference to Examples. However, it should be understood that the present is not restricted by the specific Examples.

Example

Preparation 1: Preparation of crystalline amlodipine camsylate

12.25 g (0.03 mol) of amlodipine (Hanmi Pharm. Co. Ltd.) was dissolved in 50 ml of methanol, cooled to 10°C, and a solution of 7.8 g (0.336 mol) of (1S)-(−)-10-camphor sulfonic acid (Aldrich) in 19.5 ml of methanol was gradually added thereto. After the reaction mixture was stirred at room temperature for 2 hours, the solid formed was filtered, washed with 25 ml of methanol, and dried to obtain 16.7 g (yield: 86.8%) of the title compound in the form of a white crystal.
Preparation of amorphous amlodipine camsylate

Example 1

7.841 mg of crystalline amlodipine camsylate obtained from Preparation 1 was dissolved in a mixed solution of ethanol/methylene chloride (20/80 (w/w)) to a concentration of about 100 mg/ml. The resulting solution was subjected to spray drying under the conditions listed below, followed by further drying at 60°C for 1 hour and storing in a container having silica gel desiccant to obtain dry amorphous amlodipine camsylate:

<Spray Drying Conditions>
1) Spray dryer: Buchi Minispray dryer B-191
2) Inlet and outlet temperatures: 80°C and 52°C, respectively,
3) Air flow: 500 NI/h, and
4) Pumping rate: 12% (about 120ml spraying per an hour)

Preparation of amorphous amlodipine camsylate composite

Example 2

The procedure of Example 1 was repeated except that 1.159 mg of anhydrous silica was used together with 7.841 mg of crystalline amlodipine camsylate to obtain dry amorphous amlodipine camsylate composite.

Example 3

The procedure of Example 1 was repeated except that 1.159 mg of Tween 80 was used together with 7.841 mg of crystalline amlodipine camsylate to obtain dry amorphous amlodipine camsylate composite.

Example 4

The procedure of Example 1 was repeated except that 1.159 mg of Tween 80 and 1.000 mg of anhydrous silica were used together with 7.841 mg of crystalline amlodipine camsylate to obtain dry amorphous amlodipine camsylate composite.

Example 5

The procedure of Example 1 was repeated except that 2.159 mg of
hydroxypropylmethylcellulose was used together with 7.841 mg of crystalline amlodipine camsylate to obtain dry amorphous amlodipine camsylate composite.

Example 6

The procedure of Example 1 was repeated except 2.159 mg of hydroxypropylmethylcellulose and 1.000 mg of anhydrous silica were used together with 7.841 mg of crystalline amlodipine camsylate to obtain dry amorphous amlodipine camsylate composite.

Example 7

The procedure of Example 1 was repeated except that 1.159 mg of Tween 80, 2.000 mg of hydroxypropylmethylcellulose and 1.000 mg of anhydrous silica were used together with 7.841 mg of crystalline amlodipine camsylate to obtain dry amorphous amlodipine camsylate composite.

Example 8

The procedure of Example 1 was repeated except that 2.159 mg of microcrystalline cellulose was used together with 7.841 mg of crystalline amlodipine camsylate to obtain dry amorphous amlodipine camsylate composite.

Example 9

The procedure of Example 1 was repeated except that 2.159 mg of microcrystalline cellulose, 1.000 mg of Tween 80 and 1.000 mg of anhydrous silica were used together with 7.841 mg of crystalline amlodipine camsylate to obtain dry amorphous amlodipine camsylate composite.

Preparation of a tablet containing amorphous amlodipine camsylate

Example 10

7.841 mg of the dry amorphous amlodipine camsylate obtained in Example 1, 119.159 mg of microcrystalline cellulose, 63 mg of calcium phosphate, 6 mg of sodium starch glycolate and 2 mg of magnesium stearate
were mixed and the resulting mixture was then pressed into tablets using a conventional tablet making machinery.

**Example 11**

The procedure of Example 10 was repeated except that 40 mg of Tween 80 was further used.

**Experimental Example 1: X-ray Diffraction and Differential Scanning Calorimetry (DSC) Analysis**

Crystalline amlodipine camsylate obtained in Preparation 1 and the inventive amorphous amlodipine camsylate obtained in Example 1 were analyzed with an X-ray diffractometer and DSC. The results are shown in FIGS. 1 to 4.

From FIGS. 1 and 2 showing X-ray diffraction scans of the crystalline amlodipine camsylate and the inventive amlodipine camsylate, it can be seen that the inventive amlodipine camsylate is amorphous.

Generally, an amorphous material has absorption peaks at low temperature due to unstableness but as can be shown in Figs 3 and 4, the absorption peak temperature of the inventive amorphous amlodipine camsylate is similar to that of the crystalline amlodipine camsylate. That is, the inventive amorphous amlodipine camsylate has a sufficient thermodynamic stability.

**Experimental Example 2: Solubility Test**

An amlodipine salt preferably has a solubility in water of more than 1 mg/ml at pH 1 to 7.5, particularly at the blood pH value of 7.4. Accordingly, the solubility and saturation pH of the inventive amorphous amlodipine camsylates prepared in Example 1 were measured and compared with those of amlodipine besylate (Korean Patent Publication No. 1995-7228) and crystalline amlodipine camsylate obtained in Preparation 1 (WO 02/079158 A1). The measurement was performed according to the procedure described in the Korean Pharmacopoeia (Korean Ministry of Health and Welfare, General principle of medical supplies, Vol. 1, Clause 29,
the 7th revision) which comprises the steps of dissolving each compound in distilled water to saturation, analyzing the saturated solution with liquid chromatography, and measuring the dissolved amount of each compound based on the amount of amlodipine. The results are shown in Table 1.

<table>
<thead>
<tr>
<th>Salt</th>
<th>Solubility (mg/ml)</th>
<th>Saturation pH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crystalline amlodipine besylate</td>
<td>2.35</td>
<td>6.2</td>
</tr>
<tr>
<td>Crystalline amlodipine camsylate</td>
<td>1.42</td>
<td>6.2</td>
</tr>
<tr>
<td>Amorphous amlodipine camsylate</td>
<td>6.59</td>
<td>6.2</td>
</tr>
</tbody>
</table>

As shown in Table 1, the solubility of the inventive amorphous amlodipine camsylate is 3 to 5 times higher than that of crystalline amlodipine besylate and crystalline amlodipine camsylate at the same saturation pH.

Experimental Example 3: Stability Test

A tablet or capsule ought to be stable in the solid state. Accordingly, the time-dependent stability of the tablet obtained in Example 10 was measured and compared with that of an amorphous amlodipine besylate tablet. Specifically, each tablet was stored under accelerated aging conditions (a temperature of 40±2 °C and a relative humidity of 75±5 %), and after 2 and 4 months, the remaining amount of active amlodipine was determined with a liquid chromatography. The results are shown in Table 2.

<table>
<thead>
<tr>
<th>Test tablet</th>
<th>Initial</th>
<th>2 months</th>
<th>4 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amorphous amlodipine camsylate tablet</td>
<td>100.3± 0.9%</td>
<td>99.0± 0.7%</td>
<td>98.0± 1.3%</td>
</tr>
<tr>
<td>Amorphous amlodipine besylate tablet</td>
<td>102.7± 1.3%</td>
<td>92.7± 1.8%</td>
<td>-</td>
</tr>
</tbody>
</table>
As shown in Table 2, amorphous amlodipine besylate tablet underwent about 10% degradation during 2 months, while the inventive amorphous amlodipine camsylate tablet was stable.

While the invention has been described with respect to the specific embodiments, it should be recognized that various modifications and changes may be made by those skilled in the art to the invention which also fall within the scope of the invention as defined as the appended claims.
What is claimed is:

1. A method for preparing an amorphous amlodipine camsylate by dissolving a crystalline amlodipine camsylate in an organic solvent and removing the solvent from the resulting solution.

2. The method of claim 1, wherein the organic solvent is selected from the group consisting of ketones, alcohols, nitriles, ethers, esters, chlorinated solvents and a mixture thereof.

3. The method of claim 2, wherein the organic solvent is a mixture of ethanol and methylene chloride.

4. The method of claim 1, wherein the solvent is removed from the solution by spray drying, roller drying, solvent precipitation, freeze drying or rapid solvent evaporation.

5. The method of claim 4, wherein the solvent is removed by spray drying using argon, nitrogen, carbon dioxide or air as a drying gas.

6. An amorphous amlodipine camsylate prepared by the method of claim 1.

7. A pharmaceutical composition for treating cardiovascular diseases comprising the amorphous amlodipine camsylate of claim 6 as an active ingredient.
FIG. 3
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC7 C07D 211/84

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC C07D, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean Patents and Application for Inventions since 1975

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS online (STN), Medline

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>WO 02/053538 A1 (Bioorganics B.V.) 11. July 2002 See the whole document</td>
<td>1-7</td>
</tr>
<tr>
<td>Y</td>
<td>WO 02/053539 A1 (Bioorganics B.V.) 11. July 2002 See the whole document</td>
<td>1-7</td>
</tr>
<tr>
<td>A</td>
<td>WO 02/053135 A1 (Bioorganics B.V.) 11. July 2002 See the whole document</td>
<td>1-7</td>
</tr>
</tbody>
</table>

☐ Further documents are listed in the continuation of Box C. ☑ See patent family annex.

Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search 22 APRIL 2004 (22.04.2004)

Date of mailing of the international search report 27 APRIL 2004 (27.04.2004)

Name and mailing address of the ISA/KR

Korean Intellectual Property Office
920 Dunsan-dong, Seo-gu, Daejeon 302-701, Republic of Korea
Facsimile No. 82-42-472-7140

Authorized officer

SIHN, YOUNG SIHN

Telephone No. 82-42-481-8162

Form PCT/ISA/210 (second sheet) (January 2004)
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>EP1309556A1</td>
<td>14.05.2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO02053538A1</td>
<td>11.07.2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO02053539A1</td>
<td>11.07.2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR2002076561A</td>
<td>11.10.2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO02079158A1</td>
<td>10.10.2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA2433366A1</td>
<td>11.07.2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE20116723U1</td>
<td>17.01.2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO02053135A1</td>
<td>11.07.2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO02053535A2</td>
<td>11.07.2002</td>
</tr>
</tbody>
</table>